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Background: Many patients with chronic obstructive pulmonary disease continue to   experience 
significant functional limitation despite the use of both long-acting anticholinergic and beta-
agonist inhalers. Theophylline is a widely available medication which may further improve 
lung function and exercise performance. Previous studies evaluating the effects of theophylline 
on exercise capacity in chronic obstructive pulmonary disease (COPD) have demonstrated 
heterogeneous results.
Methods: We performed a randomized placebo-controlled double-blind pilot study assessing 
the effects of theophylline on constant load exercise duration and lung function, involving 
24 COPD patients already treated with long-acting inhaled beta-agonist and long-acting anti-
cholinergic bronchodilator therapy.
Results: Analyzable data was available in 10 of 12 subjects in the treatment arm and 11 of 
12 subjects in the control arm. Theophylline was associated with a 26.1% (95% confidence 
interval [CI]: −17.3–69.5) improvement in exercise duration compared to placebo. Four of 10 
treated patients demonstrated an improvement in exercise duration exceeding the minimum 
clinically important difference of 33%, compared to 1 of 11 controls (P = 0.15). Furthermore, 
peak ventilation was reduced by 11.1%, (95% CI: 0.77–21.5) which may suggest improvements 
in gas exchange. There were no significant observed differences in resting lung function nor 
measures of dyspnea between the two treatment groups.
Conclusions: Our study demonstrated a trend, but not a statistically significant improvement in 
exercise duration and a reduction in peak ventilation with theophylline. Based on the observed 
mean differences and standard deviations in this pilot study, a randomized controlled trial would 
require 45 subjects in each arm to detect a significant change in exercise duration.
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Introduction
Over the last decade, long-acting inhaled bronchodilators have become a mainstay 
of treatment for chronic obstructed pulmonary disease (COPD). Compared to their 
short-acting counterparts, long-acting bronchodilators have been shown to provide 
greater dyspnea relief, improved lung function and reduced exacerbation rates.1–3 
Unfortunately, patients with severe COPD may continue to experience significant 
symptoms, despite use of both long-acting beta-agonists and anticholinergics. For 
these patients, it has been suggested that theophylline may be added4,5 although the 
evidence supporting the use of theophylline in a combination regimen is limited. 
Theophylline causes bronchodilation by increasing cyclic adenosine monophosphate 
via the inhibition of phosphodiesterase. It has been shown that theophylline may 
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reduce symptoms and hyperinflation, and improve exercise 
duration in patients with COPD.6 Furthermore, theophylline 
is inexpensive and easy to administer. Despite its advantages 
however, the use of theophylline is limited by its potential 
toxicities7 and drug interactions.
Few studies have evaluated the effects of theophylline 
in combination with long-acting bronchodilators. Zuwallack 
et al8 evaluated the effect of theophylline in combination 
with salmeterol. In those patients able to tolerate theo-
phylline, theophylline with salmeterol produced greater 
improvements in forced expiratory volume in 1 second 
(FEV1) and dyspnea than either therapy alone. Cazzola and 
Matera9 published the only study evaluating the effects of 
  theophylline, in combination with both long-acting anticho-
linergics and beta-agonists (tiotropium and formoterol). They 
found no significant improvement in FEV1 with the use of 
  theophylline but acknowledged that their study may have 
been underpowered.
It is possible that FEV1 may not be a sufficiently sensi-
tive measure of bronchodilator response. A previous study 
by McKay et al10 using constant load treadmill testing dem-
onstrated that theophylline improved exercise duration by 
48% in patients with severe COPD. Tsukino et al11 demon-
strated statistically significant but relatively smaller effects 
of theophylline on exercise capacity using an incremental 
cycle ergometer protocol. The Tsukino study did suggest 
that the effects of theophylline were additive to ipratropium. 
The McKay and Tsukino studies were able to demonstrate 
significant results despite enrolling only 20 and 21 patients, 
respectively, although other studies did not find any effect 
of theophylline on exercise capacity.12
The heterogeneity of previous study results makes 
sample size predictions for a randomized, controlled trial 
on this topic challenging. Consequently we designed a pilot 
study   evaluating the effects of theophylline on constant load 
exercise duration in COPD patients already treated with both 
long-acting anticholinergic and beta-agonist inhalers. The 
goals of the study included an assessment of not only the 
effect of theophylline on constant exercise duration but 
the range (standard deviation) of response in this patient 
population. It is hoped that these results would inform the 
design of future studies.
Methods
We performed a prospective randomized double-blinded 
placebo controlled trial evaluating the short-term (4 weeks) 
effects of theophylline on exercise duration and lung function 
in patients already receiving both tiotropium and a   long-acting 
beta-agonist (salmeterol or formoterol). Twenty-four patients 
with moderate-to-severe COPD who were already using 
chronic tiotropium and long-acting beta agonists were ran-
domized to receive either: (a) 4 weeks of oral theophylline 
dosed to achieve therapeutic blood levels, or (b) identical-
appearing placebo capsules.
Patients were recruited from the outpatient practices of 
academic respirologists in a tertiary care setting. All patients 
had to have a clinical diagnosis of COPD from their referring 
physician as well as an FEV1 of ,60% predicted and FEV1/
forced vital capacity [FVC] ratio ,70%, and no significant 
reversibility with short-acting bronchodilator (,12% change 
in FEV1). All patients had to be on stable doses of tiotropium 
18 µg once daily (qd) and either salmeterol 50 µg twice daily 
(bid) or formoterol 12 µg bid for at least 2 months. The use 
of inhaled corticosteroids was permitted as long as there 
were no dose changes over the last 2 months. All patients 
had to be clinically stable, with no exacerbations within the 
previous 2 months.
Exclusion criteria included the presence of lung disease 
other than COPD, any comorbidity that could potentially 
affect exercise capacity or ability to tolerate theophylline, 
and any medication that could interact with theophylline. 
Patients who were currently using theophylline or had used 
theophylline in the past were excluded as this could poten-
tially bias the results. Patients on long-term oral steroids or 
who were concurrently participating in a pulmonary reha-
bilitation program were also excluded as these factors could 
potentially affect peripheral muscle function. Patients unable 
to demonstrate evidence of either respiratory or cardiac 
limitation on cardiopulmonary exercise testing as defined in 
the American Thoracic Society/American College of Chest 
Physicians statement on cardiopulmonary exercise testing13 
were also excluded.
Study participation consisted of three visits for pulmonary 
function testing and exercise testing, with 1–3 additional 
short visits in-between for monitoring bloodwork.
Visit 1
After confirmation of eligibility and informed consent, 
patients underwent full pulmonary function testing followed 
by an incremental cardiopulmonary exercise test to assess 
maximal work rate. Incremental exercise testing was per-
formed on an electronically braked cycle-ergometer, using 
20 watt increments every 2 minutes. The maximal work rate 
attained in the incremental test was used to calculate the 
load for subsequent constant load tests (75% of the maximal 
workload). After a 30-minute recovery period, a practice 
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constant load exercise test was performed to familiarize 
patients with the exercise protocol and minimize any learning 
effects for future tests.
Visit 2
Subjects returned within 1 week of visit 1. During this visit, the 
Baseline Dyspnea Index was administered and patients under-
went repeat pulmonary function testing and the first constant 
load (75% of peak workload attained on incremental testing) 
exercise test. After completion of the constant load exercise 
test, subjects were then randomized to treatment with either 
placebo or theophylline therapy. Randomization was con-
ducted using a computer generated variable-block   algorithm. 
The patients and investigators (NV and CT) responsible for 
testing, data gathering, and data analysis were blinded to the 
theophylline allocation during the conduct of the study.
The form of theophylline used for this study was a 
24-hour sustained release formulation. Theophylline was 
initially administered at doses of 400, 600, or 800 mg qd, 
depending on body weight (10 mg/kg of body weight, with 
a 25% dose reduction for patients aged .65 years). Evening 
dosing was recommended so that peak blood levels would 
be present during the following morning. Both placebo and 
theophylline were administered in the form of identical 
capsules. The theophylline capsules used for the study were 
produced by overencapsulating half-tablets of sustained-
release theophylline (200 per study capsule).
Regardless of randomization assignment, all subjects 
were asked to return for routine blood work within 5–7 days 
of starting the medication. Blood was drawn in the morning, 
at the time peak levels are expected (8–12 hours following the 
last dose of theophylline). Patients enrolled in the treatment 
arm had adjustments in their theophylline dose, depending on 
their blood level to achieve a blood level within the therapeu-
tic range of 55–110 µmol/L. To maintain blinding, patients on 
placebo also underwent bloodwork and random sham-dosing 
adjustments were made to their placebo regimen. If dosing 
adjustments were required, repeat theophylline levels were 
measured 5–7 days after the dose change. This was repeated 
until bloodwork results were within the therapeutic range. 
Two physicians (GA and KA) were responsible for dosing 
adjustments and bloodwork monitoring. These investigators 
were unblinded and therefore were not involved in study data 
acquisition nor assessment of study outcomes.
Visit 3
Subjects returned for visit 3, 4 weeks after visit 2. On this 
visit, subjects had bloodwork to confirm that theophylline 
levels were within the therapeutic range. As with the second 
visit, subjects underwent pulmonary function testing as well 
as a constant load cardiopulmonary exercise test. Changes 
in symptoms were assessed using the transitional dyspnea 
index.
The study protocol was approved by the Ottawa Hospital 
Research Ethics Board (#2006036-01H).
Outcome measures
The primary outcome measure was the percentage of change 
in the duration of constant load exercise (done at 75% of 
maximal work rate), measured in seconds from baseline 
(visit 2) compared to visit 3 for each treatment group. 
  Secondary outcome measures included changes from visit 2 
to visit 3 in expiratory flows (FEV1, FVC), dyspnea, and 
exercise responses (see Table 1).
Sample size and statistical analysis
As mentioned earlier, it was not possible to derive a reliable 
sample size from previous studies due to their heterogeneous 
results, hence the “pilot” nature of the study. Baseline data 
was summarized as means (standard deviation) by patient 
group. The primary outcome (% change in exercise duration 
between visits 2 and 3) in the two groups was compared 
using an unpaired Student’s t-test. Secondary outcomes were 
compared with the Student’s t-test or Wilcoxon signed-rank 
test where appropriate. Univariate correlational analyses were 
performed to assess for any relationship between baseline 
pulmonary function measures or exercise results and response 
to theophylline.
Results
Between May 2006 and March 2010, 27 patients underwent 
a visit 1 assessment. Three of 27 patients did not meet inclu-
sion criteria and were not randomized (Figure 1).
Although the use of inhaled corticosteroids was not 
required, 23 of 24 patients were using inhaled   corticosteroids 
in addition to tiotropium and a long-acting beta-agonist 
(Table 2). All enrolled subjects had at least Global Initia-
tive for Chronic Obstructive Pulmonary Disease (GOLD) 
stage 3 COPD by spirometric criteria, with a mean FEV1 of 
approximately 30% (range 15%–47%) (Table 2).
Three of the 24 randomized patients were excluded after 
randomization, two of whom were randomized to the theo-
phylline arm. One theophylline patient developed intolerable 
nausea despite blood levels that were near the lower limit of the 
therapeutic range. The other theophylline patient was admit-
ted to hospital with acute coronary syndrome, within 1 week 
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Table 1 Pulmonary function and cardiopulmonary exercise results after treatment
Placebo (n = 11) Theophylline (n = 10) Difference in means 95% CI for Dif.
Change in FEV1, % predicted 1.82 (3.52) 0.70 (3.20) −1.12 (−4.20–1.96)
Change in TLC, % predicted −0.62 (5.01) 2.70 (8.68) 3.32 (−4.02–10.67)
Change in RV, % predicted −5.62 (15.36) 11.10 (18.00) 16.72 (−0.26–33.71)
Change in DLCO, % predicted −1.09 (3.36) −1.30 (7.21) −0.21 (−5.62–5.20)
Transitional dyspnea index 0.27 (2.33) 1.20 (2.20) 0.93 (−1.15–3.00)
Constant load exercise data
  Change in exercise duration (seconds) 20.36 (67.62) 62.70 (163.00) 42.34 (−78.69–163.40)
  Change in exercise duration (% change) 2.80 (27.58) 28.91 (57.65) 26.11 (−17.29–69.53)
  Change in VO2, % predicted 4.09 (11.72) −1.60 (10.25) −5.69 (−15.79–4.41)
  Change in VE, % predicted −0.36 (13.15) −11.50 (8.87) −11.14 (−21.50–0.77)
  Change in HR, % predicted 1.45 (4.70) 3.80 (5.09) 2.35 (−2.13–6.82)
  Change in resting IC 0.13 (0.25) 0.07 (0.32) −0.06 (−0.32–0.20)
  Change in peak IC 0.03 (0.30) 0.14 (0.31) 0.11 (−0.17–0.39)
Isotime exercise data
  Change in VO2 (mL/min) 0.08 (0.22) −0.02 (0.13) −0.10 (−0.28–0.07)
  Change in HR (beats/min) −0.33 (6.95) 4.70 (10.02) 5.03 (−3.41–13.48)
  Change in VE (L/min) 1.56 (5.95) 0.44 (4.27) −1.12 (−6.09–3.86)
  Change in IC (L) 0.09 (0.26) 0.16 (0.36) 0.07 (−0.23–0.38)
  Change in dyspnea (Borg scale) −0.17 (1.75) 0.45 (2.43) 0.62 (−1.46–2.69)
  Change in leg fatigue (Borg scale) −0.33 (1.66) 0.90 (2.42) 1.23 (−0.80–3.27)
Note: Values in placebo and theophylline columns represent means, followed by standard deviations. 
Abbreviations: CI, confidence intervals; DLCO, diffusing capacity; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; HR, heart rate; IC, inhibitory 
capacity; RV, residual volume; TLC, total lung capacity; VE, ventilatory efficiency; VO2, oxygen consumption.
of randomization. Although the patient reported compliance 
with the study medication, blood levels drawn at the time of 
admission did not detect theophylline. One patient randomized 
to the placebo arm was excluded due to inability to provide 
maximal results on visit 2 exercise testing. As per protocol, 
this patient should have been excluded before randomization 
but this did not occur due to investigator error. The decision to 
exclude this patient from analysis was made before unblinding 
and data analysis. All other patients demonstrated evidence of 
ventilatory limitation during exercise testing.
All patients randomized to theophylline demonstrated 
blood levels within the target range at the time of visit 3. 
The ten patients with complete data in the theophylline 
arm demonstrated a mean improvement of 28.9% (95% 
confidence intervals [CI]: −12.3–70.2) in exercise duration, 
compared to 2.8% (95% CI: −15.7–21.3) for the 11 patients in 
the placebo arm (Table 1). The between-group difference in 
change in exercise duration was 26.1% (95% CI: −17.3–69.5) 
or 42.3 seconds (95% CI: −78.7–163.4). Given the wide 
standard deviation in exercise duration for the theophylline 
arm, the difference in exercise duration was not statistically 
significant (P = 0.22).
In addition to exercise duration, we also measured the 
effects of theophylline on other exercise parameters, symp-
toms, and lung function (Table 1). Exercise parameters, 
such as ventilation, inspiratory capacity and heart rate were 
compared at both peak exercise as well as isotime. Isotime 
analysis was conducted by comparing exercise parameters 
during the same time point. Isotime was determined by 
the shorter of the two exercise tests during visits 2 and 3. 
  Theophylline was not associated with any improvements 
in resting lung function, however it was associated with a 
small but statistically significant reduction in peak ventilation 
(−11.1%; 95% CI: −0.77–21.5).
As noted above, there were two significant adverse events 
(intolerable nausea and acute coronary syndrome) in the 
theophylline group compared to none in the placebo group, 
although it is difficult to attribute the acute coronary syndrome 
to the use of theophylline, given undetectable blood levels at 
the time of presentation. Overall, side-effects were reported 
by five of 12 patients in the theophylline group, compared to 
two of 12 patients in the placebo group. Reported symptoms 
were abdominal cramping, headache, and insomnia. Three 
of 12 patients randomized to theophylline complained of 
abdominal cramping compared to none in the placebo group. 
Two patients on theophylline also complained of headaches 
compared to none in the placebo group. Two patients in each 
group complained of insomnia. Apart from the one patient 
who discontinued theophylline due to nausea, all other side-
effects were mild and self-limited.
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Discussion
Our study is the first to evaluate the effects of theophylline 
on exercise capacity in COPD patients already treated with 
combination long-acting inhaled bronchodilator therapy. We 
demonstrated that it is feasible to conduct a study evaluating 
theophylline in patients with severe COPD. The majority of 
the patients in our study were able to tolerate theophylline 
in doses sufficient to achieve what would be traditionally 
considered a therapeutic level. The dropout rate was only 
12.5%, which is comparable or lower than previous reports. 
However, the standard deviation in exercise duration for 
patients assigned to the theophylline arm is larger than that 
seen in patients assigned to placebo, and larger than seen 
with inhaled long-acting bronchodilator studies employing 
similar methodology.14–16
A recent study has suggested that the minimum clini-
cally important difference (MCID) for constant load exercise 
is 33%.17 We also analyzed the effects of theophylline on 
exercise duration by determining the proportion of subjects in 
each arm who demonstrated a MCID in constant load exercise 
duration. Four of 10 theophylline-treated patients demonstrated 
an improvement in exercise duration that was greater than the 
MCID, compared to only one of 11 placebo-treated patients. 
However, these results were also nonsignificant (P = 0.15).
Given the marked heterogeneity of the theophylline 
effects on exercise duration, we performed univariate   analysis 
27 patients screened 
24 patients randomized
12 assigned to
theophylline  
12 assigned to
placebo 
2 dropped out: 
– 1 hospitalized with 
acute coronary syndrome
– 1 developed intolerable 
gastrointestinal side-
effects on theophylline 
1 excluded due to
submaximal exercise 
results
10 completed
the study  
11 completed
the study  
3 excluded: 
− 1 withdrew consent 
− 1 hospitalized for exacerbation 
− 1 had submaximal exercise results 
Figure 1 Patient flow diagram.
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on the ten patients who completed the   theophylline arm of 
the study to assess whether any factors on pre-treatment pul-
monary function or exercise data that could identify patients 
who might benefit from theophylline, via regression analysis 
(Table 3). We found that neither baseline FEV1, FVC, residual 
volume, dyspnea severity (as assessed by baseline dyspnea 
index), nor any resting exercise   parameters predicted the 
Table 3 Correlations between the baseline pulmonary function 
and  exercise  measurements  with  change  in  exercise  duration   
(% change)
Pearson correlation coefficient 
(P-value)
FEV1, % predicted 0.38 (0.283)
FVC, % predicted 0.297 (0.404)
TLC, % predicted 0.35 (0.327)
RV, % predicted 0.219 (0.544)
DLCO, % predicted 0.87 (0.001)
Peak VO2, % predicted 0.37 (0.290)
Peak VO2/kg, % predicted 0.297 (0.404)
Peak HR, % predicted 0.364 (0.301)
Peak VE, % predicted 0.135 (0.710)
Notes: The Pearson correlation coefficient was used to assess the strength of 
linear association between each variable and the percent change in exercise duration 
on theophylline. Diffusing capacity showed a strong positive correlation with the 
percent change in exercise duration (r = 0.87). For other variables, there was no 
evidence of having a significant linear association with change in exercise duration.
Abbreviations: CI, confidence intervals; DLCO, diffusing capacity; FEV1, forced 
expiratory  volume  in  1  second;  FVC,  forced  vital  capacity;  HR,  heart  rate;  IC, 
inhibitory capacity; RV, residual volume; TLC, total lung capacity; VE, ventilatory 
efficiency; VO2, oxygen consumption.
Table 2 Demographic and baseline data
Placebo (n = 11) 95% CI Theophylline (n = 10) 95% CI
Age 65 65.5
Sex
  Male 9 (82%) 8 (80%)
  Female 2 (18%) 2 (20%)
Medications
  Tiotropium 11 (100%) 10 (100%)
  Salmeterol 8 (73%) 7 (70%)
  Formoterol 3 (27%) 3 (30%)
  Inhaled corticosteroids 11 (100%) 9 (90%)
Pulmonary function
  FEV1, % predicted 29.54 (11.25) (21.98, 37.11) 30.90 (9.39) (24.18, 37.61)
  FEV1/FVC ratio 38.45 (11.08) (31.01, 45.90) 31.80 (7.42) (26.49, 37.11)
  Total lung capacity, % predicted 105.20 (16.38) (92.63, 117.80) 114.10 (17.02) (101.90, 126.30)
  Residual volume, % predicted 178.70 (45.02) (144.10, 213.30) 180.90 (34.95) (155.90, 205.90)
  Diffusing capacity, % predicted 42.27 (12.92) (33.60, 50.95) 46.90 (10.09) (39.68, 54.12)
Incremental exercise
  VO2 , % predicted 37.91 (14.16) (28.40, 47.42) 39.50 (11.10) (31.56, 47.44)
  Peak workload (Watts) 49.09 (22.56) (33.93, 64.25) 48.00 (16.86) (35.94, 60.06)
  Peak heart rate, % predicted 76.36 (9.71) (69.84, 82.88) 79.60 (8.72) (73.36, 85.84)
  Peak ventilation, % predicted 99.36 (23.32) (83.70, 115.00) 93.70 (13.12) (84.32, 103.10)
  Baseline dyspnea index 5.91 (1.76) (4.73, 7.09) 5.30 (1.16) (4.47, 6.13)
Note: Values are means followed by (standard deviation). 
Abbreviations: CI, confidence intervals; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; VO2, oxygen consumption.
magnitude of response to theophylline.   However, we did 
find a positive correlation between diffusing capacity and 
improvements in exercise duration on theophylline (r = 0.87), 
meaning that subjects with greater diffusing capacity tended 
to demonstrate greater improvements in exercise capacity on 
theophylline. This is a novel finding and could potentially 
help predict which patients are more likely to respond to 
theophylline. However, we acknowledge that one positive cor-
relation among nine separate univariate analyses could occur 
by chance and confirmation with future studies is required 
before any definitive conclusions could be drawn.
The reduction in peak ventilation is of uncertain 
significance. In the context of a trend toward improvement 
in exercise capacity, it is possible that the reduction in 
 ventilation represents improved gas exchange and ventilatory 
efficiency (lower ventilatory efficiency/oxygen consumption 
ratio). However, it should be noted that this finding was not 
observed in previous exercise studies with theophylline6,10 and 
consequently, confirmation with a larger study is required.
A post-hoc analysis using our study’s data suggests that a 
total of 90 patients (not accounting for dropouts) would have 
been required to have 80% power to detect a difference in 
exercise duration of 26%. Our study’s relatively small sample 
size did not allow us to detect potential effects of theophylline 
on pulmonary function or other exercise parameters, such as 
heart rate response.
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Since the conception of our study, some authors have 
suggested the combination of theophylline and inhaled 
corticosteroids may have a modest improvement on some 
measures of inflammation and lung function.18 It is notable 
that all but one of our study subjects was on inhaled steroids 
concurrently, although our protocol did not require use of 
inhaled corticosteroids for study inclusion. The possibility 
that there may be a beneficial interaction between theophyl-
line and inhaled steroids is interesting but ultimately does 
not change the conclusions of our study, as we were not able 
to detect a significant improvement in exercise capacity with 
the addition of theophylline. Reanalysis of our study results 
excluding the one patient not taking inhaled corticosteroids 
did not significantly change our study results.
Conclusion
Our study did not find a statistically significant improvement 
in exercise duration with theophylline compared to placebo, 
in patients with COPD already treated with combination 
long-acting inhaled bronchodilator therapy. Although there 
was a mean improvement in exercise duration of 26%, the 
result was not statistically significant due to large variations 
in individual patient responses to theophylline. Our results do 
however suggest that further investigation is warranted on the 
issue. In our study, theophylline was tolerated by the majority 
of subjects, and four of 10 patients able to tolerate theophylline 
did demonstrate a clinically meaningful improvement in exer-
cise capacity. Our small sample size precludes any definitive 
conclusions on the utility of theophylline but if our results are 
validated in a larger study, this would have important clinical 
implications on the treatment of COPD, particularly given the 
low cost and accessibility of theophylline.
This is the first study to evaluate the effect of theophyl-
line on exercise performance in COPD patients already on 
long-acting anticholinergic and beta-agonist therapy. Our 
results suggest that some patients may experience a clinically 
significant improvement in exercise capacity with theophyl-
line, but further study is needed before definitive conclusions 
may be drawn.
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